Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12027793 | 0.78 | CYP2C9 (0.38) | CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL953686 | 0.78 | ERN1 (0.44) | CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL2256657 | 0.76 | CYP2C9 (0.40) | CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL288166 | 0.74 | CES2 (0.34) | — | |
| SCHEMBL1786797 | 0.74 | ALDH1A1 (0.32) | — | |
| SCHEMBL31685229 | 0.74 | CYP2C9 (0.46) | CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL415893 | 0.74 | CYP2C9 (0.46) | CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL2257043 | 0.73 | HTR2C (0.42) | CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL12235261 | 0.71 | ERN1 (0.42) | CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL878717 | 0.70 | L3MBTL1 (0.52) | CYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250128188-A1 | BORONIC ACID CONTAINING AFFINITY MEMBRANES | DONALDSON COMPANY, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | CYP2C9 2438/4885CYP3A4 1734/4885CYP2C19 2309/4885 |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | CYP2C9 4394/4885CYP3A4 3961/4885CYP2C19 3667/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | CYP2C9 2438/4885CYP3A4 1734/4885CYP2C19 2309/4885 |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | CYP2C9 2438/4885CYP3A4 1734/4885CYP2C19 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.